Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide

Molica, Stefano; Rossi, Marco; Allsup, David

doi:10.1159/000533349

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the targeted inhibition of BTK can effectively treat CLL. With the advent of BTK inhibitors, the treatment armamentarium of CLL has expanded, offering an effective and well-tolerated therapeutic option in both treatment-naïve (TN) and relapsed/refractory (R/R) settings [ 34 – 37 ]. BTK inhibitors are recommended for the treatment of patients with CLL/SLL regardless of age, fitness, deletion of chromosome 17 (del [17p]) and/or TP53 mutation, and immunoglobulin heavy-chain variable-region (IGHV) gene mutational status.…”

Section: Clinical Recommendations For Btk Inhibitors In the Treatment...mentioning

confidence: 99%

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Song,

Wu,

Shen

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies. Considering the unmet need of evidence on BTK inhibitors in all clinical settings and to standardize the use of BTK inhibitors available in mainland China, Taiwan, Hong Kong, and Macau regions, this consensus has been formulated for the treatment of various B-cell malignancies based on the clinical practice and available evidences on the use of BTK inhibitors. The recommendations of this consensus will provide guidance to physicians and clinical researchers on the effective treatment of B-cell malignancies with BTK inhibitors.

show abstract

Section: Clinical Recommendations For Btk Inhibitors In the Treatment...mentioning

confidence: 99%

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Song,

Wu,

Shen

et al. 2023

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide

Cited by 1 publication

References 5 publications

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

Contact Info

Product

Resources

About